Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

These Donors Equally Suitable for Pediatric HSCT

Biol Blood Marrow Transplant; ePub 2017 Sep 25; Friedrich, et al

Human leukocyte antigen (HLA)-matched siblings—irrespective of sex or donor/recipient sex mismatch—are equally suitable donors for pediatric hematopoietic stem-cell transplantation (HSCT), according to a retrospective study involving 244 individuals. Participants were pediatric patients who received their first myeloablative sibling-donor HSCT between 1998 and 2012. Among the results:

  • 17% of patients who survived past engraftment experienced grade II-IV acute GVHD (aGVHD).
  • 14% who survived ≥100 days developed chronic GVHD (cGVHD).
  • Risk of GVHD and death increased with age.
  • Female donor sex and sex-mismatch did not impact aGVHD development.
  • cGVHD increased when female donors were aged ≥12 years.
  • No cGVHD was seen in patients aged <10 years who received a 6/6 HLA-matched marrow HSCT.
  • Survival was primarily driven by diagnosis.

Citation:

Friedrich P, Guerra-Garcia P, Stetson A, Duncan C, Lehmann L. Young female donors do not increase risk of GVHD or impact overall outcomes in pediatric HLA-matched sibling HSCT. [Published online ahead of print September 25, 2017]. Biol Blood Marrow Transplant. doi:10.1016/j.bbmt.2017.09.014.

This Week's Must Reads

Cochrane on Use of TPO-RAs to Prevent, Treat CIT, Cochrane; 2017 Nov 27; Zhang, Chuai, Nie, et al

Guideline on Preventing VTE in Pediatric Cancer, J Thromb Haemost; ePub 2017 Nov 27; Tullius, et al

Conditioning Regimens After HCT Compared in ALL, Biol Blood Marrow Transplant; ePub 2017 Nov 29; Kebriaei, et al

Acute Kidney Injury in Young Allo-HCT Recipients, Biol Blood Marrow Transplant; ePub 2017 Nov 28; Koh, et al

Moral Distress in HCT Professionals Evaluated, Biol Blood Marrow Transplant; ePub 2017 Nov 28; Neumann, et al

Must Reads in Cellular Therapy

Acute Kidney Injury in Young Allo-HCT Recipients, Biol Blood Marrow Transplant; ePub 2017 Nov 28; Koh, et al

Anthracycline-Related CV Dysfunction Evaluated, Cancer; ePub 2017 Nov 7; Armenian, Mertens, et al

FDA Approves Prevymis for Certain HSCT Recipients, Merck news release; 2017 Nov 9

G-CSF Priming’s Impact on Bone Marrow Harvest, Biol Blood Marrow Transplant; ePub 2017 Oct 23; Furey, et al

Timing of G-CSF Initiation After Auto PBSCT, Biol Blood Marrow Transplant; ePub 2017 Oct 20; Singh, et al